Skip to main content

Table 1 Baseline patient characteristics of 122 patients with CDI

From: Polymerase chain reaction ribotyping of Clostridium difficileisolates in Qatar: a hospital-based study

Variable Category No. Of subjects n (%)
Total number of subjects Qatari residents 122
Gender Males 72 (59%)
Females 50 (41%)
Age 1-14 yrs 23 (18.9%)
15-30 yrs 15 (12.3%)
31-50 yrs 21 (17.2%)
51-64 yrs 22 (18%)
≥ 65 yrs 41 (33.6%)
Hospital acquired CDI   98 (80.3%)
Community acquired CDI   14 (11.5%)
Medical Records not available   10 (8.2%)
Antibiotics used prior to CDI (some patients were on >1): Tazocin 55 (45.1%)
Third generation Cephalosporins 50 (41%)
Amoxicillin 22 (18%)
Meropenom 20 (16.4%)
Ciprofloxacin 20 (16.4%)
Vancomycin 15 (12.3%)
Co-trimoxazole 10 (8.2%)
Azithromycin 9 (9.8%)
Amikacin 6 (7.4%)
Teicoplanin 4 (3.3%)
Nitrofurantoin 2 (1.6%)
Doxycyclin 2 (1.6%)
Tigecyclin 1 (0.8%)
Linezolid 1 (0.8%)
Cloxacillin 1 (0.8%)
Colistin 1(0.8%)
Moxifloxacin, 1 (0.8%)
Ampicillin 1 (0.8%)
Septrin 1 (0.8%)
Amygdalin 1 (0.8%)